Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Holdings Decreased by Federated Hermes Inc.

Federated Hermes Inc. trimmed its position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 9.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 492,803 shares of the company's stock after selling 49,276 shares during the quarter. Federated Hermes Inc. owned approximately 0.86% of Harmony Biosciences worth $16,957,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of HRMY. GAMMA Investing LLC increased its holdings in shares of Harmony Biosciences by 92.6% in the 4th quarter. GAMMA Investing LLC now owns 907 shares of the company's stock valued at $31,000 after acquiring an additional 436 shares during the period. Mendota Financial Group LLC lifted its stake in shares of Harmony Biosciences by 24,125.0% in the 4th quarter. Mendota Financial Group LLC now owns 969 shares of the company's stock worth $33,000 after acquiring an additional 965 shares during the period. KBC Group NV increased its stake in shares of Harmony Biosciences by 79.9% during the fourth quarter. KBC Group NV now owns 1,844 shares of the company's stock worth $63,000 after acquiring an additional 819 shares during the period. PNC Financial Services Group Inc. lifted its position in Harmony Biosciences by 28.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,328 shares of the company's stock valued at $80,000 after purchasing an additional 519 shares during the period. Finally, Avanza Fonder AB purchased a new position in shares of Harmony Biosciences during the 4th quarter worth approximately $145,000. 86.23% of the stock is owned by hedge funds and other institutional investors.

Harmony Biosciences Stock Performance

Shares of NASDAQ HRMY traded down $1.46 during trading on Tuesday, reaching $28.07. The stock had a trading volume of 191,176 shares, compared to its average volume of 672,249. The firm's 50 day moving average price is $33.69 and its two-hundred day moving average price is $34.70. Harmony Biosciences Holdings, Inc. has a one year low of $26.47 and a one year high of $41.61. The stock has a market cap of $1.61 billion, a PE ratio of 13.30, a P/E/G ratio of 0.47 and a beta of 0.80. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last posted its quarterly earnings results on Tuesday, February 25th. The company reported $0.85 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.74 by $0.11. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The company had revenue of $201.30 million for the quarter, compared to the consensus estimate of $201.25 million. During the same period last year, the firm posted $0.45 EPS. The company's revenue for the quarter was up 19.5% on a year-over-year basis. On average, research analysts forecast that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current fiscal year.

Insider Transactions at Harmony Biosciences

In other news, CEO Jeffrey M. Dayno sold 19,293 shares of the company's stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $40.13, for a total value of $774,228.09. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jeffrey Dierks sold 1,629 shares of the firm's stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $38.02, for a total transaction of $61,934.58. The disclosure for this sale can be found here. Over the last quarter, insiders sold 72,452 shares of company stock worth $2,831,679. Insiders own 30.80% of the company's stock.

Analysts Set New Price Targets

Several research analysts have recently issued reports on HRMY shares. HC Wainwright reaffirmed a "buy" rating and set a $70.00 price target on shares of Harmony Biosciences in a research note on Tuesday, April 8th. Mizuho increased their target price on Harmony Biosciences from $42.00 to $44.00 and gave the company an "outperform" rating in a report on Tuesday, March 18th. Deutsche Bank Aktiengesellschaft started coverage on Harmony Biosciences in a research report on Tuesday, February 11th. They issued a "buy" rating and a $55.00 price objective on the stock. Finally, Needham & Company LLC reissued a "buy" rating and set a $50.00 price objective on shares of Harmony Biosciences in a research note on Tuesday, April 8th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $53.33.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.